智通财经APP讯,东曜药业-B(01875)发布公告,截至2025年3月31日止3个月期间,本集团的营业收入同比增长13%至人民币 2.52亿元,主要系由于自研产品收入稳步增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.